{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:54:16Z","timestamp":1776815656994,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenems are essential antibiotics used to treat severe nosocomial infections. However, the misuse of these antibiotics has led to the emergence of carbapenem-resistant organisms (CROs), posing significant public health threats. This study aims to determine the prevalence and phenotypic profile of carbapenem resistance (CR) in multidrug-resistant Gram-negative bacteria (MDR-GNB) in selected healthcare facilities in the United Arab Emirates (UAE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective study was conducted across 65 healthcare facilities in Dubai and the Northern Emirates (NE) from January 2018 to June 2021. Results from GNB isolates - including\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      ,\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      , and\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      - obtained from various clinical samples were collected and assessed for CR using CLSI guidelines at all locations. MDR-CRO prevalence was calculated within each bacterial group using total isolates of that group as the denominator at each time point.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 77,228 GNB collected, 3,829 (5%) MDR-CROs were identified. Within the MDR-CROs subset,\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      accounted for 65.8% (48.7% of which were\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      ),\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      28.6%, and\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      5.6%. In contrast, period prevalence calculated within total isolates of each organism group was highest for MDR-CR\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      (22.8%), followed by MDR-CR\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      (12.9%), and MDR-CR\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      (5.6%). A significant increase in MDR-CR\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      was observed in the NE in mid-2021, which coincided with the COVID-19 pandemic. Hospitals were the primary source of MDR-CR isolates, accounting for more than 90% of\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      and\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      cases, and 62.6% of\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      cases. Carbapenems nonsusceptibility varied among bacterial species.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study highlights the increasing CR burden of\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      ,\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      , and\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      in the UAE. Regional variations in resistance, particularly the MDR-CR\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      surge in the NE during the COVID-19 pandemic, stress the need for tailored infection control measures and antimicrobial stewardship.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13007-0","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:04:34Z","timestamp":1773410674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and phenotypic characterization of carbapenem resistance in multidrug-resistant Gram-negative bacteria across selected healthcare facilities in the United Arab Emirates: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7143-8486","authenticated-orcid":false,"given":"Rula A. M.","family":"Aljaede","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-4783","authenticated-orcid":false,"given":"Semira Abdi","family":"Beshir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-1923","authenticated-orcid":false,"given":"Ammar Ali Saleh","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6659-5049","authenticated-orcid":false,"given":"Ramadan","family":"Elkalmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-7147","authenticated-orcid":false,"given":"Eiman Shamseldin Al Gailani","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4530-0562","authenticated-orcid":false,"given":"Amany Hamed Mahmoud","family":"Khedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4660-4848","authenticated-orcid":false,"given":"Dujana","family":"ALHamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jainamboo","family":"Meera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zulfa","family":"AlDeesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"13007_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2049936115621709","volume":"3","author":"G Meletis","year":"2016","unstructured":"Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3:15\u201321. https:\/\/doi.org\/10.1177\/2049936115621709.","journal-title":"Ther Adv Infect Dis"},{"key":"13007_CR2","doi-asserted-by":"publisher","first-page":"FSO438","DOI":"10.2144\/fsoa-2019-0098","volume":"6","author":"AA Elshamy","year":"2020","unstructured":"Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Futur Sci OA. 2020;6:FSO438. https:\/\/doi.org\/10.2144\/fsoa-2019-0098.","journal-title":"Futur Sci OA"},{"key":"13007_CR3","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1093\/jac\/dky168","volume":"73","author":"SK Son","year":"2018","unstructured":"Son SK, Lee NR, Ko JH, Choi JK, Moon SY, Joo EJ, et al. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73:2631\u201342. https:\/\/doi.org\/10.1093\/jac\/dky168.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 7","key":"13007_CR4","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","volume":"69","author":"P Nordmann","year":"2019","unstructured":"Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521\u20138. https:\/\/doi.org\/10.1093\/cid\/ciz824.","journal-title":"Clin Infect Dis"},{"key":"13007_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/antibiotics9040186","volume":"9","author":"DH Halat","year":"2020","unstructured":"Halat DH, Moubareck CA. The current burden of carbapenemases: review of significant properties and dissemination among gram-negative bacteria. Antibiot (Basel). 2020;9:186. https:\/\/doi.org\/10.3390\/antibiotics9040186.","journal-title":"Antibiot (Basel)"},{"key":"13007_CR6","volume-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Geneva: WHO; 2017. https:\/\/www.who.int\/publications\/i\/item\/WHO-EMP-IAU-2017.12."},{"key":"13007_CR7","doi-asserted-by":"publisher","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2019. Atlanta (GA): US Department of Health and Human Services; 2019. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html. https:\/\/doi.org\/10.15620\/cdc:82532","DOI":"10.15620\/cdc:82532"},{"key":"13007_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jgar.2021.02.033","volume":"25","author":"A Sleiman","year":"2021","unstructured":"Sleiman A, Fayad AGA, Banna H, Matar GM. Prevalence and molecular epidemiology of carbapenem-resistant Gram-negative bacilli and their resistance determinants in the Eastern Mediterranean Region over the last decade. J Glob Antimicrob Resist. 2021;25:209\u201321. https:\/\/doi.org\/10.1016\/j.jgar.2021.02.033.","journal-title":"J Glob Antimicrob Resist"},{"key":"13007_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/microorganisms8101626","volume":"8","author":"M Nasser","year":"2020","unstructured":"Nasser M, Palwe S, Bhargava RN, Feuilloley MGJ, Kharat AS. Retrospective analysis on antimicrobial resistance trends and prevalence of \u03b2-lactamases in Escherichia coli and ESKAPE pathogens isolated from Arabian patients during 2000\u20132020. Microorganisms. 2020;8:1626. https:\/\/doi.org\/10.3390\/microorganisms8101626.","journal-title":"Microorganisms"},{"key":"13007_CR10","doi-asserted-by":"publisher","first-page":"1247627","DOI":"10.3389\/fpubh.2023.1247627","volume":"11","author":"J Thomsen","year":"2023","unstructured":"Thomsen J, Abdulrazzaq NM, Alrand H, Ahmed AE, Yousef AF, Alblooshi A, et al. Surveillance of antimicrobial resistance in the United Arab Emirates: the early implementation phase. Front Public Health. 2023;11:1247627. https:\/\/doi.org\/10.3389\/fpubh.2023.1247627.","journal-title":"Front Public Health"},{"key":"13007_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijid.2022.04.034","volume":"120","author":"\u00c1 Sonnevend","year":"2022","unstructured":"Sonnevend \u00c1, Abdulrazzaq N, Ghazawi A, Thomsen J, Bharathan G, Makszin L, et al. The first nationwide surveillance of carbapenem-resistant Enterobacterales in the United Arab Emirates: increased association of Klebsiella pneumoniae CC14 clone with Emirati patients. Int J Infect Dis. 2022;120:103\u201312. https:\/\/doi.org\/10.1016\/j.ijid.2022.04.034.","journal-title":"Int J Infect Dis"},{"key":"13007_CR12","doi-asserted-by":"publisher","unstructured":"Centers for Disease Control and Prevention. Covid-19: U.S. impact on antimicrobial resistance. Atlanta (GA): US Department of Health and Human Services. 2022. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/COVID-19.html. https:\/\/doi.org\/10.15620\/cdc:117915","DOI":"10.15620\/cdc:117915"},{"key":"13007_CR13","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.3390\/jcm10102067","volume":"10","author":"W M\u0119drzycka-Dabrowska","year":"2021","unstructured":"M\u0119drzycka-Dabrowska W, Lange S, Zorena K, Dabrowski S, Ozga D, Tomaszek L. Carbapenem-resistant Klebsiella pneumoniae infections in ICU COVID-19 patients: a scoping review. J Clin Med. 2021;10:2067. https:\/\/doi.org\/10.3390\/jcm10102067.","journal-title":"J Clin Med"},{"key":"13007_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3201\/eid2811.220415","volume":"28","author":"GR Thomas","year":"2022","unstructured":"Thomas GR, Corso A, Paster\u00e1n F, Shal J, Sosa A, Pillonetto M, et al. Increased detection of carbapenemase-producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerg Infect Dis. 2022;28:1\u20138. https:\/\/doi.org\/10.3201\/eid2811.220415.","journal-title":"Emerg Infect Dis"},{"key":"13007_CR15","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Eaune (PA): CLSI; 2020. https:\/\/clsi.org."},{"key":"13007_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x.","journal-title":"Clin Microbiol Infect"},{"key":"13007_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/cid\/cix246","volume":"65","author":"JH Rex","year":"2017","unstructured":"Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, et al. Progress in the fight against multidrug-resistant bacteria, 2005\u20132016. Clin Infect Dis. 2017;65:141\u20136. https:\/\/doi.org\/10.1093\/cid\/cix246.","journal-title":"Clin Infect Dis"},{"key":"13007_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1128\/JCM.41.1.351-358.2003","volume":"41","author":"CD Steward","year":"2003","unstructured":"Steward CD, Mohammed JM, Swenson JM, Stocker SA, Williams PP, Gaynes RP, et al. Antimicrobial susceptibility testing of carbapenems. J Clin Microbiol. 2003;41:351\u20138. https:\/\/doi.org\/10.1128\/JCM.41.1.351-358.2003.","journal-title":"J Clin Microbiol"},{"key":"13007_CR19","volume-title":"Global antimicrobial resistance surveillance system (GLASS)","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global antimicrobial resistance surveillance system (GLASS). Geneva: WHO; 2021. https:\/\/www.who.int\/initiatives\/glass."},{"key":"13007_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/jac\/dkh295","volume":"54","author":"JT Magee","year":"2004","unstructured":"Magee JT, Al Shafi K, Banerjee C, Carbarns NJB, Cefai C, El-Bouri K, et al. Effects of duplicate and screening isolates on surveillance of community and hospital antibiotic resistance. J Antimicrob Chemother. 2004;54:155\u201362. https:\/\/doi.org\/10.1093\/jac\/dkh295.","journal-title":"J Antimicrob Chemother"},{"key":"13007_CR21","unstructured":"Ministry of Health and Prevention (UAE). UAE national surveillance system for antimicrobial resistance (INFORMA). 2019. https:\/\/mohap.gov.ae\/en\/open-data\/mohap-open-data"},{"key":"13007_CR22","unstructured":"Ministry of Health and Prevention (UAE). UAE national surveillance of antimicrobial resistance: annual report 2019. 2021. https:\/\/mohap.gov.ae\/en\/open-data\/mohap-open-data"},{"key":"13007_CR23","unstructured":"Ministry of Health and Prevention (UAE). UAE national surveillance of antimicrobial resistance: annual report 2020. 2022. https:\/\/mohap.gov.ae\/en\/open-data\/mohap-open-data"},{"key":"13007_CR24","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1016\/S1473-3099(18)30414-6","volume":"18","author":"RA Moghnieh","year":"2018","unstructured":"Moghnieh RA, Kanafani ZA, Tabaja HZ, Sharara SL, Awad LS, Kanj SS. Epidemiology of common resistant bacterial pathogens in the countries of the Arab League. Lancet Infect Dis. 2018;18:e379\u201394. https:\/\/doi.org\/10.1016\/S1473-3099(18)30414-6.","journal-title":"Lancet Infect Dis"},{"key":"13007_CR25","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/jam.15130","volume":"131","author":"M Nguyen","year":"2021","unstructured":"Nguyen M, Joshi SG. Carbapenem resistance in Acinetobacter baumannii and its importance in hospital-acquired infections: a scientific review. J Appl Microbiol. 2021;131:2715\u201338. https:\/\/doi.org\/10.1111\/jam.15130.","journal-title":"J Appl Microbiol"},{"key":"13007_CR26","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1093\/jac\/dkaa194","volume":"75","author":"TM Rawson","year":"2020","unstructured":"Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020;75:1681\u20134. https:\/\/doi.org\/10.1093\/jac\/dkaa194.","journal-title":"J Antimicrob Chemother"},{"key":"13007_CR27","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/pathogens10081006","volume":"10","author":"K Rangel","year":"2021","unstructured":"Rangel K, Chagas TPG, De-Simone SG. Acinetobacter baumannii infections in times of the COVID-19 pandemic. Pathogens. 2021;10:1006. https:\/\/doi.org\/10.3390\/pathogens10081006.","journal-title":"Pathogens"},{"key":"13007_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","volume":"27","author":"ZR Palacios-Baena","year":"2021","unstructured":"Palacios-Baena ZR, Giannella M, Manissero D, Rodr\u00edguez-Ba\u00f1o J, Viale P, Lopes S, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect. 2021;27:228\u201335. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.016.","journal-title":"Clin Microbiol Infect"},{"key":"13007_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijantimicag.2017.03.012","volume":"50","author":"AM Kelly","year":"2017","unstructured":"Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents. 2017;50:127\u201334. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.03.012.","journal-title":"Int J Antimicrob Agents"},{"key":"13007_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13756-020-00736-3","volume":"9","author":"D Hamza","year":"2020","unstructured":"Hamza D, Dorgham S, Ismael E, El-Moez SIA, Elhariri M, Elhelw R, et al. Emergence of \u03b2-lactamase- and carbapenemase-producing Enterobacteriaceae at integrated fish farms. Antimicrob Resist Infect Control. 2020;9:67. https:\/\/doi.org\/10.1186\/s13756-020-00736-3.","journal-title":"Antimicrob Resist Infect Control"},{"key":"13007_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12879-024-09015-7","volume":"24","author":"B Schlosser","year":"2024","unstructured":"Schlosser B, Weikert B, Fucini GB, Kohlmorgen B, Kola A, Weber A, et al. Risk factors for transmission of carbapenem-resistant Acinetobacter baumannii in outbreak situations: results of a case-control study. BMC Infect Dis. 2024;24:120. https:\/\/doi.org\/10.1186\/s12879-024-09015-7.","journal-title":"BMC Infect Dis"},{"key":"13007_CR32","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1128\/JCM.00341-10","volume":"48","author":"N Woodford","year":"2010","unstructured":"Woodford N, Eastaway AT, Ford M, Leanord A, Keane C, Quayle RM, et al. Comparison of BD Phoenix, VITEK 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. J Clin Microbiol. 2010;48:2999\u20133002. https:\/\/doi.org\/10.1128\/JCM.00341-10.","journal-title":"J Clin Microbiol"},{"key":"13007_CR33","doi-asserted-by":"publisher","first-page":"DC05","DOI":"10.7860\/jcdr\/2020\/46140.14271","volume":"14","author":"S Mohapatra","year":"2020","unstructured":"Mohapatra S, Kumar A, Bir R, Tyagi S, Sood S, Das BK, et al. Use of ertapenem as a marker for detection of carbapenem resistance in Enterobacteriaceae. J Clin Diagn Res. 2020;14:DC05\u20138. https:\/\/doi.org\/10.7860\/jcdr\/2020\/46140.14271.","journal-title":"J Clin Diagn Res"},{"key":"13007_CR34","doi-asserted-by":"publisher","first-page":"127249","DOI":"10.1016\/j.micres.2022.127249","volume":"266","author":"J Ma","year":"2023","unstructured":"Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023;266:127249. https:\/\/doi.org\/10.1016\/j.micres.2022.127249.","journal-title":"Microbiol Res"},{"issue":"Suppl 7","key":"13007_CR35","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565\u201375. https:\/\/doi.org\/10.1093\/cid\/ciz830.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13007-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:34:51Z","timestamp":1776814491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13007-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13007"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13007-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and was approved by the Dubai Pharmacy College Research Ethics Committee (REC\/PG\/2021\/15), the Institutional Review Board of Gulf Medical University (IRB\/EXTERNAL\/66\/SEP-2021), and the Dubai Scientific Research Ethics Committee (DSREC-SR-08\/2021_03). Owing to its retrospective design, the requirement for informed consent was waived. All patient data were treated confidentially, with access restricted to researchers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"804"}}